Literature DB >> 17205196

DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis.

M Dierssen1, M Martínez de Lagrán.   

Abstract

DYRKs (dual-specificity tyrosine-regulated kinases) are an emerging family of evolutionarily conserved dual-specificity kinases that play key roles in cell proliferation, survival, and development. The research in the last years suggests a relevant conserved function during neuronal development, related to proliferation and/or differentiation for DYRK1A. It is expressed in neural progenitor cells and has been proposed to participate in the signaling mechanisms that regulate dendrite differentiation. In Drosophila, disruption of the homolog minibrain gene results in flies with reduced neuroblast proliferation, decreased numbers of central brain neurons, and learning/memory deficits. Knockout DYRK1A mice are embryonic lethal, and heterozygotes show decreased viability and region-specific reductions in brain size. In humans, DYRK1A has been proposed to be involved in the neurodevelopmental alterations associated with Down syndrome. The large number of protein interaction and putative substrates described for DYRK1A suggest multiple pathways and functions to be involved in its developmental function. This review focuses on the functional role that DYRK1A plays in brain development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17205196      PMCID: PMC5917402          DOI: 10.1100/tsw.2006.319

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  36 in total

1.  BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients.

Authors:  Asma Tlili; Alexander Hoischen; Clémentine Ripoll; Eva Benabou; Anne Badel; Anne Ronan; Renaud Touraine; Yann Grattau; Samantha Stora; Bregje van Bon; Bert de Vries; Björn Menten; Nele Bockaert; Joseph Gecz; Stylianos E Antonarakis; Dominique Campion; Marie-Claude Potier; Henri Bléhaut; Jean-Maurice Delabar; Nathalie Janel
Journal:  Mol Neurobiol       Date:  2012-06-05       Impact factor: 5.590

Review 2.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

Review 3.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

4.  Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes.

Authors:  Mireia Vilardell; Axel Rasche; Anja Thormann; Elisabeth Maschke-Dutz; Luis A Pérez-Jurado; Hans Lehrach; Ralf Herwig
Journal:  BMC Genomics       Date:  2011-05-11       Impact factor: 3.969

5.  Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Jessica Yu; Jeesun Kim; Larisa V Lysenko; Zheng Zeng; Y Eugene Yu; William C Mobley
Journal:  Neurobiol Dis       Date:  2017-03-22       Impact factor: 5.996

6.  Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.

Authors:  Nana Jin; Xiaomin Yin; Jianlan Gu; Xinhua Zhang; Jianhua Shi; Wei Qian; Yuhua Ji; Maohong Cao; Xiaosong Gu; Fei Ding; Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

Review 7.  Using C. elegans to decipher the cellular and molecular mechanisms underlying neurodevelopmental disorders.

Authors:  Carlos Bessa; Patrícia Maciel; Ana João Rodrigues
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

8.  Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A.

Authors:  Sergi Aranda; Mónica Alvarez; Silvia Turró; Ariadna Laguna; Susana de la Luna
Journal:  Mol Cell Biol       Date:  2008-08-04       Impact factor: 4.272

9.  Development of a sensitive non-radioactive protein kinase assay and its application for detecting DYRK activity in Xenopus laevis oocytes.

Authors:  Eva Lilienthal; Katharina Kolanowski; Walter Becker
Journal:  BMC Biochem       Date:  2010-05-20       Impact factor: 4.059

10.  CK2 is a novel negative regulator of NADPH oxidase and a neuroprotectant in mice after cerebral ischemia.

Authors:  Gab Seok Kim; Joo Eun Jung; Kuniyasu Niizuma; Pak H Chan
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.